Ken Takeshita, Corporate Vice President, Clinical Research and Development, Celgene, has led the clinical program in lymphoma and chronic lymphocytic leukemia (CLL) since 2008. This resulted in the approval of lenalidomide in mantle cell lymphoma, Istodax in peripheral and cutaneous T cell lymphomas, as well as initiating the on-going lenalidomide registration trials in follicular and large cell lymphomas and evaluation of newer Celgene pipeline assets in CLL and lymphoma, including pleotropic pathway modulators (CC-122), epigenetic hypomethylating agents (CC-486), immuno-oncology assets (durvalumab) and CAR T cell technology. Dr Takeshita also served as the founding general manager of Celgene KK (Japan) from 2005 to 2007, starting the Japanese Revlimid program resulting in approvals in multiple myeloma and deletion 5q myelodysplastic syndrome. Prior to joining the biotechnology field, Dr Takeshita was on the faculty in Hematology at Yale University School of Medicine USA and New York University School of Medicine, USA. Dr Takeshita received an A.B. Degree in Molecular Biology from Harvard University, an M.D. from Yale University and post-doctoral training in developmental biology at Yale and in hematopoiesis at University of Tokyo.